Competition is in full swing in the paroxysmal nocturnal hemoglobinuria (PNH) market, which is currently dominated by AstraZeneca's treatments such as Soliris and Ultomiris, with the introduction of new drugs that have new mechanisms of action soon to emerge in the market. Recently, Handok's Empaveli is nearing reimbursement in Korea, and Novartis has filed for domestic marketing authorization of its new drug Fabhalta. Amid the introduction of such new drugs, AstraZeneca is defending its market by receiving approval for Voydeya, which is used as an adjuvant therapy with Soliris and Ultomiris.

According to industry sources on the 6th, Handok's Empaveli (pegcetacoplan) was approved adequate for reimbur